midazolam has been researched along with zithromax in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, JT; Neuvonen, PJ; Olkkola, KT | 1 |
| Idänpään-Heikkilä, JJ; Mattila, MJ; Vanakoski, J | 1 |
| Laufen, H; Leitold, M; Scharpf, F; Wildfeuer, A; Yeates, RA; Zimmermann, T | 1 |
| Laufen, H; Yeates, RA; Zimmermann, T | 1 |
| Laufen, H; Schumacher, T; Yeates, RA; Zimmermann, T | 1 |
| Ito, K; Itoh, T; Kanamitsu, S; Ogihara, K | 1 |
| Babu, TA | 1 |
1 review(s) available for midazolam and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for midazolam and zithromax
| Article | Year |
|---|---|
Azithromycin does not increase plasma concentrations of oral midazolam.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Psychomotor Performance | 1995 |
Azithromycin does not alter the effects of oral midazolam on human performance.
Topics: Adult; Arousal; Azithromycin; Cross-Over Studies; Double-Blind Method; Drug Synergism; Erythromycin; Female; Humans; Male; Midazolam; Psychomotor Performance | 1994 |
Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Half-Life; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Psychomotor Performance; Sleep | 1996 |
Interaction between midazolam and clarithromycin: comparison with azithromycin.
Topics: Adult; Analysis of Variance; Anti-Anxiety Agents; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Sleep | 1996 |
Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
Topics: Anti-Anxiety Agents; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam | 1997 |
12 other study(ies) available for midazolam and zithromax
| Article | Year |
|---|---|
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Hydroxylation; Macrolides; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Time Factors | 2003 |
Prolonged sedation following administration of oral midazolam.
Topics: Azithromycin; Child, Preschool; Conscious Sedation; Drug Interactions; Humans; Hypnotics and Sedatives; Male; Midazolam | 2013 |